Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$86.18 - $99.03 $259,660 - $298,377
-3,013 Reduced 19.34%
12,568 $1.21 Million
Q2 2021

Aug 09, 2021

SELL
$89.43 - $102.27 $368,719 - $421,659
-4,123 Reduced 20.92%
15,581 $1.52 Million
Q1 2021

May 10, 2021

BUY
$87.57 - $119.4 $1.73 Million - $2.35 Million
19,704 New
19,704 $1.92 Million
Q4 2020

Feb 10, 2021

SELL
$86.91 - $108.33 $7.35 Million - $9.17 Million
-84,618 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$96.16 - $135.15 $1,057 - $1,486
11 Added 0.01%
84,618 $8.14 Million
Q2 2020

Aug 10, 2020

SELL
$85.09 - $130.36 $595 - $912
-7 Reduced 0.01%
84,607 $10.3 Million
Q1 2020

May 12, 2020

SELL
$75.11 - $113.76 $292,628 - $443,208
-3,896 Reduced 4.4%
84,614 $7.32 Million
Q4 2019

Feb 06, 2020

BUY
$86.8 - $118.57 $260 - $355
3 Added 0.0%
88,510 $9.51 Million
Q2 2019

Aug 12, 2019

BUY
$72.24 - $91.27 $585,144 - $739,287
8,100 Added 10.07%
88,507 $7.47 Million
Q1 2019

May 10, 2019

BUY
$69.31 - $91.53 $1.94 Million - $2.56 Million
28,007 Added 53.45%
80,407 $7.08 Million
Q4 2018

Feb 08, 2019

SELL
$68.32 - $124.36 $430,415 - $783,468
-6,300 Reduced 10.73%
52,400 $3.74 Million
Q3 2018

Nov 13, 2018

SELL
$98.88 - $125.85 $5.1 Million - $6.49 Million
-51,600 Reduced 46.78%
58,700 $7.22 Million
Q1 2018

May 15, 2018

SELL
$75.88 - $92.43 $675,332 - $822,627
-8,900 Reduced 7.47%
110,300 $9.15 Million
Q2 2017

Aug 07, 2017

BUY
N/A
119,200
119,200 $5.48 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.2B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Gam Holding Ag Portfolio

Follow Gam Holding Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gam Holding Ag, based on Form 13F filings with the SEC.

News

Stay updated on Gam Holding Ag with notifications on news.